Mpox vaccine (2024)

Concepts

• vaccines
• primary vaccination
• mpox vaccine
• mpox
• vaccine
• vaccination
• adults
• vaccinia virus
• vaccinia
• disease

Location

London

Description

A contract for the supply of Mpox vaccine

Total Quantity or Scope

A contract for a vaccine indicated for primary vaccination against smallpox, Mpox and disease caused by vaccinia virus in adults.Delivery of more than 150,000 doses will be required over the initial term, with an option to extend for up to an additional 24 months.

Award Detail

Renewal Options

The contract has the option to be extended for up to an additional 24 months

Award Criteria

CPV Codes

• 33651600 - Vaccines

Indicators

• Options are available.
• Award on basis of price.

Legal Justification

There is only one manufacturer of this vaccine approved for use in the UK, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) of the Public Contracts Regulations 2015.

Other Information

Value - The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier. The contract is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.